Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
I129798-50mg | 50mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $39.90 | |
I129798-100mg | 100mg | In stock | $64.90 | |
I129798-250mg | 250mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $146.90 | |
I129798-500mg | 500mg | In stock | $148.90 | |
I129798-1g | 1g | In stock | $268.90 | |
I129798-5g | 5g | In stock | $1,206.90 | |
I129798-25g | 25g | In stock | $5,431.90 |
Toll-like receptor 7 agonist; immunomodulator
Synonyms | HMS3715N19 | Imiquimod 100 microg/mL in Acetonitrile | Imiquimod- Bio-X | Aldara (TN) | DTXSID7041047 | HY-B0180 | S 26308 | AB00399298-05 | IMIQUIMOD [ORANGE BOOK] | YH44175 | 1-isobutylimidazo[4,5-c]quinolin-4-amine | HB3109 | IMIQUIMOD [JAN] | 4-Amino- |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | Toll-like receptor 7 agonist. Activates NF-κB and stimulates pro-inflammtory cytokines. Immunomodulator, antiviral and antitumor agent. Active in vivo and in vitro . |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Agonist of TLR7 |
Note | Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Toxic, refer to SDS for further information. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | Product Description Imiquimod (R 837) is an immune response modifier that acts as a toll-like receptor 7 agonist. Product Application Imiquimod is a caspase 3 activator which acts as an immunomodulator and displays antiviral and anti-tumor activity. It is a patient-applied cream used for the treatment of genital warts and basal cell carcinoma. It is also used to cure actinic keratosis on the face and scalp. It belongs to a group of drugs called immune response modifiers, which work by activating the immune system to fight abnormal skin growth. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Pubchem Sid | 488183396 |
---|---|
Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488183396 |
IUPAC Name | 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine |
INCHI | InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17) |
InChi Key | DOUYETYNHWVLEO-UHFFFAOYSA-N |
Canonical SMILES | CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N |
Isomeric SMILES | CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N |
WGK Germany | 3 |
RTECS | NJ5903450 |
PubChem CID | 57469 |
Molecular Weight | 240.31 |
Reaxy-Rn | 7710060 |
DrugBank Ligand | DB00724 |
---|---|
Wikipedia | Imiquimod |
ChEBI | CHEBI:36704 |
CAS Registry No. | 99011-02-6 |
PubChem CID | 57469 |
ChEMBL Ligand | CHEMBL1282 |
RCSB PDB Ligand | 6T0 |
PEP | imiquimod |
DrugCentral Ligand | 1429 |
PubChem SID | 488183396 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
B2309991 | Certificate of Analysis | Nov 15, 2024 | I129798 |
B2309953 | Certificate of Analysis | Nov 15, 2024 | I129798 |
B2309944 | Certificate of Analysis | Nov 15, 2024 | I129798 |
B2309964 | Certificate of Analysis | Nov 07, 2024 | I129798 |
B2309966 | Certificate of Analysis | Nov 07, 2024 | I129798 |
B2309986 | Certificate of Analysis | Nov 07, 2024 | I129798 |
J1810144 | Certificate of Analysis | Jul 05, 2024 | I129798 |
G2410613 | Certificate of Analysis | Mar 12, 2024 | I129798 |
G2410612 | Certificate of Analysis | Mar 12, 2024 | I129798 |
C2429503 | Certificate of Analysis | Mar 12, 2024 | I129798 |
C2429502 | Certificate of Analysis | Mar 12, 2024 | I129798 |
C2429505 | Certificate of Analysis | Mar 12, 2024 | I129798 |
C2429512 | Certificate of Analysis | Mar 12, 2024 | I129798 |
C2223364 | Certificate of Analysis | Jan 04, 2024 | I129798 |
E1810042 | Certificate of Analysis | Oct 17, 2023 | I129798 |
E1810043 | Certificate of Analysis | Oct 07, 2023 | I129798 |
G2103012 | Certificate of Analysis | Apr 14, 2023 | I129798 |
B2309982 | Certificate of Analysis | Jan 03, 2023 | I129798 |
L2312048 | Certificate of Analysis | Jan 03, 2023 | I129798 |
J1810143 | Certificate of Analysis | Oct 15, 2022 | I129798 |
C2223405 | Certificate of Analysis | Dec 25, 2021 | I129798 |
Solubility | Soluble in DMSO (4 mg/ml ,warming to 60 °C for 15 minutes) DMF (1.5 mg/ml) at 37 °C, and water (slightly soluble) at 37 °C. Insoluble in ethanol. |
---|---|
Melt Point(°C) | 297~299℃ |
1. Haifeng Ni, Sunxiang Qian, Jie Lu, Jie Feng, Xiao-zhou Mou, Jing Zhang. (2023) Natural Polysaccharide Delivery Platforms with Multiscale Structure Used for Cancer Chemoimmunotherapy. MOLECULAR PHARMACEUTICS, (28): [PMID:37752866] [10.1021/acs.molpharmaceut.3c00633] |
2. Lu Dehua, Xu Yanming, Yang Xiaodong, Li Ying, Li Mengqing, Zheng Yuanyuan, Wang Yuenan, Wang Weihu, Wang Shubin, Gao Jing, Liu Yajie. (2023) Neutrophil membrane-derived nanoparticle loading TLR7 agonists augments radiotherapy efficacy and boosts abscopal effect via regulating tumor microenvironment. Cancer Nanotechnology, 14 (1): (1-18). [PMID:] [10.1186/s12645-023-00193-8] |
3. Hong Liu, Zhenfu Wen, Haolin Chen, Zeyu Yang, Zhicheng Le, Zhijia Liu, Yongming Chen, Lixin Liu. (2022) Nanoadjuvants Actively targeting lymph node conduits and blocking tumor invasion in lymphatic vessels. JOURNAL OF CONTROLLED RELEASE, 352 (497). [PMID:36341931] [10.1016/j.jconrel.2022.10.053] |
4. Meiting Li, Yaqian Zhang, Xiaoge Zhang, Zhuoyin Liu, Junjie Tang, Miao Feng, Baizhu Chen, Dalin Wu, Jie Liu. (2022) Degradable Multifunctional Porphyrin-Based Porous Organic Polymer Nanosonosensitizer for Tumor-Specific Sonodynamic, Chemo- and Immunotherapy. ACS Applied Materials & Interfaces, 14 (43): (48489–48501). [PMID:36281484] [10.1021/acsami.2c14776] |
5. Jiexin Li, He Ren, Yaping Sun, Gengqi Liu, Xingyue Yang, Qian Qiu, Yuanmeng Ding, Jonathan F. Lovell, Yumiao Zhang. (2021) Magnetic Metal Micelles for Enhanced Delivery of Self-Immolating CD8+ T-Cell Epitopes for Cancer Immunotherapy. CHEMISTRY OF MATERIALS, 33 (24): (9780–9794). [PMID:] [10.1021/acs.chemmater.1c03681] |
6. Lili Cheng, Xiaoge Zhang, Junjie Tang, Qijun Lv, Jie Liu. (2021) Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy. BIOMATERIALS, 275 (120964). [PMID:34147721] [10.1016/j.biomaterials.2021.120964] |
7. Zhang Lirong, Zhang Jingjing, Xu Lixia, Zhuang Zijian, Liu Jingjin, Liu Suwan, Wu Yunchao, Gong Aihua, Zhang Miaomiao, Du Fengyi. (2021) NIR responsive tumor vaccine in situ for photothermal ablation and chemotherapy to trigger robust antitumor immune responses. JOURNAL OF NANOBIOTECHNOLOGY, 19 (1): (1-16). [PMID:34001148] [10.1186/s12951-021-00880-x] |
8. Yuting Cao, Yan Zhou, Jinbin Pan, Xinyu Zhong, Jianmin Ding, Xiang Jing, Shao-Kai Sun. (2021) A general strategy towards an injectable microwave-sensitive immune hydrogel for combined percutaneous microwave ablation and immunotherapy. CHEMICAL ENGINEERING JOURNAL, 422 (130111). [PMID:] [10.1016/j.cej.2021.130111] |
9. Fan Jiang, Binbin Ding, Shuang Liang, Yajie Zhao, Ziyong Cheng, Bengang Xing, Ping'an Ma, Jun Lin. (2021) Intelligent MoS2–CuO heterostructures with multiplexed imaging and remarkably enhanced antitumor efficacy via synergetic photothermal therapy/ chemodynamic therapy/ immunotherapy. BIOMATERIALS, 268 (120545). [PMID:33253965] [10.1016/j.biomaterials.2020.120545] |
10. Zhaocheng Li, Jiyuan Gao, Zexing Xiang, Honglei Zhang, Yibei Wang, Xuefei Zhang. (2020) A pH-responsive polymer linked with immunomodulatory drugs: synthesis, characteristics and in vitro biocompatibility. JOURNAL OF APPLIED TOXICOLOGY, 41 (5): (724-735). [PMID:32776438] [10.1002/jat.4042] |
11. Xiangbo Meng, Ke Wang, Lin Lv, Ye Zhao, Chen Sun, Lianjun Ma, Bin Zhang. (2019) Photothermal/Photodynamic Therapy with Immune-Adjuvant Liposomal Complexes for Effective Gastric Cancer Therapy. PARTICLE & PARTICLE SYSTEMS CHARACTERIZATION, 36 (6): (1900015). [PMID:] [10.1002/ppsc.201900015] |
1. Haifeng Ni, Sunxiang Qian, Jie Lu, Jie Feng, Xiao-zhou Mou, Jing Zhang. (2023) Natural Polysaccharide Delivery Platforms with Multiscale Structure Used for Cancer Chemoimmunotherapy. MOLECULAR PHARMACEUTICS, (28): [PMID:37752866] [10.1021/acs.molpharmaceut.3c00633] |
2. Lu Dehua, Xu Yanming, Yang Xiaodong, Li Ying, Li Mengqing, Zheng Yuanyuan, Wang Yuenan, Wang Weihu, Wang Shubin, Gao Jing, Liu Yajie. (2023) Neutrophil membrane-derived nanoparticle loading TLR7 agonists augments radiotherapy efficacy and boosts abscopal effect via regulating tumor microenvironment. Cancer Nanotechnology, 14 (1): (1-18). [PMID:] [10.1186/s12645-023-00193-8] |
3. Hong Liu, Zhenfu Wen, Haolin Chen, Zeyu Yang, Zhicheng Le, Zhijia Liu, Yongming Chen, Lixin Liu. (2022) Nanoadjuvants Actively targeting lymph node conduits and blocking tumor invasion in lymphatic vessels. JOURNAL OF CONTROLLED RELEASE, 352 (497). [PMID:36341931] [10.1016/j.jconrel.2022.10.053] |
4. Meiting Li, Yaqian Zhang, Xiaoge Zhang, Zhuoyin Liu, Junjie Tang, Miao Feng, Baizhu Chen, Dalin Wu, Jie Liu. (2022) Degradable Multifunctional Porphyrin-Based Porous Organic Polymer Nanosonosensitizer for Tumor-Specific Sonodynamic, Chemo- and Immunotherapy. ACS Applied Materials & Interfaces, 14 (43): (48489–48501). [PMID:36281484] [10.1021/acsami.2c14776] |
5. Jiexin Li, He Ren, Yaping Sun, Gengqi Liu, Xingyue Yang, Qian Qiu, Yuanmeng Ding, Jonathan F. Lovell, Yumiao Zhang. (2021) Magnetic Metal Micelles for Enhanced Delivery of Self-Immolating CD8+ T-Cell Epitopes for Cancer Immunotherapy. CHEMISTRY OF MATERIALS, 33 (24): (9780–9794). [PMID:] [10.1021/acs.chemmater.1c03681] |
6. Lili Cheng, Xiaoge Zhang, Junjie Tang, Qijun Lv, Jie Liu. (2021) Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy. BIOMATERIALS, 275 (120964). [PMID:34147721] [10.1016/j.biomaterials.2021.120964] |
7. Zhang Lirong, Zhang Jingjing, Xu Lixia, Zhuang Zijian, Liu Jingjin, Liu Suwan, Wu Yunchao, Gong Aihua, Zhang Miaomiao, Du Fengyi. (2021) NIR responsive tumor vaccine in situ for photothermal ablation and chemotherapy to trigger robust antitumor immune responses. JOURNAL OF NANOBIOTECHNOLOGY, 19 (1): (1-16). [PMID:34001148] [10.1186/s12951-021-00880-x] |
8. Yuting Cao, Yan Zhou, Jinbin Pan, Xinyu Zhong, Jianmin Ding, Xiang Jing, Shao-Kai Sun. (2021) A general strategy towards an injectable microwave-sensitive immune hydrogel for combined percutaneous microwave ablation and immunotherapy. CHEMICAL ENGINEERING JOURNAL, 422 (130111). [PMID:] [10.1016/j.cej.2021.130111] |
9. Fan Jiang, Binbin Ding, Shuang Liang, Yajie Zhao, Ziyong Cheng, Bengang Xing, Ping'an Ma, Jun Lin. (2021) Intelligent MoS2–CuO heterostructures with multiplexed imaging and remarkably enhanced antitumor efficacy via synergetic photothermal therapy/ chemodynamic therapy/ immunotherapy. BIOMATERIALS, 268 (120545). [PMID:33253965] [10.1016/j.biomaterials.2020.120545] |
10. Zhaocheng Li, Jiyuan Gao, Zexing Xiang, Honglei Zhang, Yibei Wang, Xuefei Zhang. (2020) A pH-responsive polymer linked with immunomodulatory drugs: synthesis, characteristics and in vitro biocompatibility. JOURNAL OF APPLIED TOXICOLOGY, 41 (5): (724-735). [PMID:32776438] [10.1002/jat.4042] |
11. Xiangbo Meng, Ke Wang, Lin Lv, Ye Zhao, Chen Sun, Lianjun Ma, Bin Zhang. (2019) Photothermal/Photodynamic Therapy with Immune-Adjuvant Liposomal Complexes for Effective Gastric Cancer Therapy. PARTICLE & PARTICLE SYSTEMS CHARACTERIZATION, 36 (6): (1900015). [PMID:] [10.1002/ppsc.201900015] |